A Phase II Clinical and Translational Study of MK-2206 in Patients with Metastatic Neuroendocrine Tumors (NETs)

被引：0
|
作者：
Reidy-Lagunes, Diane [1 ,2 ]
Pietanza, M. Catherine [1 ,2 ]
Sega, Michal [1 ,2 ]
Capanu, Marinela [1 ,2 ]
Saltz, Leonard [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
来源：
PANCREAS | 2014年 / 43卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：503 / 503
页数：1
相关论文
共 50 条
  • [11] Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma.
    Ho, Alan Loh
    Foster, Nathan R.
    Meyers, Jeffrey P.
    Vasudeva, Shyamprasad Deraje
    Katabi, Nora
    Antonescu, Cristina R.
    Pfister, David G.
    Horvath, Laura E.
    Erlichman, Charles
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [12] A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
    Gupta, Shilpa
    Argiles, Guillem
    Munster, Pamela N.
    Hollebecque, Antoine
    Dajani, Olav
    Cheng, Jonathan D.
    Wang, Ruixue
    Swift, Ann
    Tosolini, Alessandra
    Piha-Paul, Sarina A.
    CLINICAL CANCER RESEARCH, 2015, 21 (23) : 5235 - 5244
  • [13] Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Tamura, Kenji
    Tanabe, Yuko
    Yonemori, Kan
    Yoshino, Takayuki
    Fuse, Nozomu
    Kodaira, Makoto
    Bando, Hideaki
    Noguchi, Kazuo
    Shimamoto, Takashi
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 409 - 416
  • [14] Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
    Toshihiko Doi
    Kenji Tamura
    Yuko Tanabe
    Kan Yonemori
    Takayuki Yoshino
    Nozomu Fuse
    Makoto Kodaira
    Hideaki Bando
    Kazuo Noguchi
    Takashi Shimamoto
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 409 - 416
  • [15] A phase II study of pemetrexed in patients (pts) with advanced neuroendocrine tumors (NETs)
    Bhargava, P.
    Earle, C. C.
    Zhu, A. X.
    Clark, J. W.
    Vincitore, M.
    Battu, S.
    Regan, E.
    Lawrence, C.
    Kulke, M. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [16] A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104)
    Ho, Alan L.
    Foster, Nathan R.
    Vasudeva, Shyamprasad Deraje
    Katabi, Nora
    Antonescu, Cristina R.
    Frenette, Gary P.
    Pfister, David G.
    Erlichman, Charles
    Schwartz, Gary K.
    CANCER, 2024, 130 (05) : 702 - 712
  • [17] Multicenter Phase II study of MK-2206 in previously treated patients (pts) with recurrent and metastatic nasopharyngeal carcinoma (NPC): Mayo Clinic Phase II Consortium (Protocol: MC1079)
    Ma, Brigette B.
    Goh, Boon Cher
    Lim, Wan Teck
    Tan, Eng Huat
    Lopes, Gilberto de Lima
    Hui, Edwin P.
    King, Ann D.
    Lo, Kwok Wai
    Loong, Herbert
    Li, Leung
    Foster, Nathan
    Kam, Michael
    Leung, Sing Fai
    Erlichman, Charles
    Chan, Anthony T. C.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [18] Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer.
    Konstantinopoulos, Panagiotis
    Makker, Vicky
    Barry, William Thomas
    Liu, Joyce
    Horowitz, Neil S.
    Birrer, Michael J.
    Doyle, L. Austin
    Berlin, Suzanne T.
    Whalen, Christin
    Van Hummelen, Paul
    Coleman, Robert L.
    Aghajanian, Carol
    Mills, Gordon B.
    Matulonis, Ursula
    Westin, Shannon Neville
    Myers, Andrea P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [19] Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Kulke, MH
    Stuart, K
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Muzikansky, A
    Vincitore, M
    Michelini, A
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 401 - 406
  • [20] Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors
    Strosberg, Jonathan R.
    Jump, Helen
    Valone, Tiffany
    Weber, Jill
    Khandelwal, Vilay H.
    Kunz, Pamela L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345